Vical Announces News Release Schedule for Third Quarter 2010 Financial Results and Plans to Host Analyst and Investor Day in New York
globenewswire
SAN DIEGO, Nov. 2, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL - News) today announced that the company will report financial results for the three months and nine months ended September 30, 2010, before the opening of trading on Tuesday, November 9.
Analyst and Investor Day
In lieu of its usual financial results conference call and webcast, Vical is hosting an Analyst and Investor Day event in New York for invited analysts and institutional investors beginning at 5:00 p.m. EST on Tuesday, November 9. A webcast of the event will be available live and archived through the Events page in the Investors section of the Vical website at www.vical.com. For further information, contact Vical's Investor Relations department by phone at (858) 646-1127 begin_of_the_skype_highlighting (858) 646-1127 end_of_the_skype_highlighting or by e-mail at info@vical.com.
Sanjiv S. Agarwala, M.D., Chief of Oncology & Hematology and Director of the Melanoma and Immunotherapy Program at St. Luke's Cancer Center (Bethlehem, PA), will present an overview on metastatic melanoma. Mark D. Pescovitz, M.D., Professor of Surgery and Microbiology & Immunology and Vice Chair of Research in Surgery at the Indiana University School of Medicine (Indianapolis, IN), will present an overview on cytomegalovirus (CMV) in the transplant setting. Vical senior management will provide overviews on the company's technologies and programs, with a focus on the Allovectin-7(R) melanoma immunotherapy program and the TransVax(TM) therapeutic CMV vaccine program.
About Vical
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at www.vical.com. |
